Malaria, acute respiratory infection Infections and Infestations Malaria
Conditions
Interventions
Patients were randomised between:
1. Treatment with Coartem® and/or cotrimoxazole based on rapid diagnosis test results and respiratory rate count
2. Presumptive treatment with Coartem®, on day three
Sponsors
UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Written informed consent from parent/guardian 2. Aged 6 to 59 months 3. Weight equals 5 kg 4. Willing to comply with the study procedures 5. History of fever within the last 24 hours or documented fever (axillary temperature equals 37.5°C)
Exclusion criteria
Exclusion criteria: 1. Severe malaria 2. Danger signs (unable to drink or eat, incoercible vomiting, convulsions, prostration) 3. History of allergic reaction to the study drugs 4. History of treatment with artemisinin derivatives in the past seven days 5. Previous participation in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical recovery rate at 72 hours after treatment (defined as apyrexia and axillary temperature less than 37.5°C). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Evaluate influence of the seasonal variation of malaria transmission on the impact, measured at eight days post onset of the treatment 2. Assess the cost-effectiveness of RDT in the context of the HMM strategy with Coartem®, measured at the end of the study 3. Describe the operational feasibility and acceptability of RDT in the context of the HMM strategy with Coartem®, measured at the end of the study | — |
Countries
Burkina Faso
Outcome results
None listed